Rare Diseases Analysis

Federal Court Litigation on Reproductive Health: Rare Disease Implications

FDA · rare disease · 5 min

EC nod for Chiesi Lojuxta for pediatric HoFH: what it means for pharma

European Commission (EC) · rare disease · 5 min

FDA Voucher Program Pause Urged: Rare Disease Policy Analysis

FDA · rare disease · 5 min

Japan Grants Orphan Status to QRX003 for Netherton Syndrome: Implications for Pharma Teams

MHLW · Netherton syndrome · 5 min

Biosimilar Uptake EU: Market Impact Post-Patent Expirations & HTA Regulation

EMA · biologics · 9 min

European Biomarker-Driven Trials: EMA Regulatory Framework & Success Rates

EMA · precision medicine · 12 min

EU HTA Regulation Impact: Effects on Rare Disease Drug Approvals & Market Access

EMA · Rare Diseases · 9 min

EU Pharmaceutical Legislation Reform: Impact on Orphan Drug Development & Market Exclusivity

EMA · Rare Diseases · 4 min

Real-World Evidence EU Drug Development: EMA's Hybrid Trial Framework

EMA · Oncology · 12 min

AI Drug Discovery EU: Accelerating Rare Disease Therapies via COMP & EMA

EMA · Rare diseases · 12 min